AKR-001, an Fc-FGF21 Analog, Showed Sustained Pharmacodynamic Effects on Insulin Sensitivity and Lipid Metabolism in Type 2 Diabetes Patients

Cell Reports Medicine
Allegra KaufmanTim Rolph

Abstract

Experimental fibroblast growth factor 21 (FGF21) analogs can improve lipid profiles in patients with metabolic diseases. However, their effects on markers of insulin sensitivity appear to be minimal, potentially because of insufficient exposure. Systemic drug levels vary from sub-pharmacological to demonstrating pharmacodynamic effects but with dose-limiting adverse events. Here we report results from a phase 1 multiple ascending dose study of AKR-001, an Fc-FGF21 fusion protein engineered for sustained systemic pharmacologic exposure, in individuals with type 2 diabetes. With a half-life of 3-3.5 days, the peak-to-trough ratio under steady-state conditions is approximately 2 following QW dosing. AKR-001 appears to demonstrate pharmacodynamic effects on serum markers of insulin sensitivity and acceptable tolerability up to and including 70 mg QW. Positive trends in lipoprotein profile, including triglycerides, non-high-density lipoprotein (non-HDL) cholesterol, HDL-C, and apolipoproteins B and C3 are consistent with other FGF21 analogs. AKR-001's clinical profile supports further evaluation as a treatment for metabolic diseases.

References

May 1, 2004·Psychonomic Bulletin & Review·Eric-Jan Wagenmakers, Simon Farrell
May 3, 2005·The Journal of Clinical Investigation·Kerry L DonnellyElizabeth J Parks
Feb 2, 2006·The Journal of Clinical Endocrinology and Metabolism·Brian R Barrows, Elizabeth J Parks
Oct 28, 2006·Endocrinology·Alexei KharitonenkovGarret J Etgen
Apr 25, 2007·Proceedings of the National Academy of Sciences of the United States of America·Yasushi OgawaMakoto Kuro-o
Mar 5, 2008·The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences·K J MelansonS B Roberts
Jul 1, 2008·Cell Metabolism·Takeshi InagakiSteven A Kliewer
Oct 7, 2008·World Journal of Gastroenterology : WJG·Olga Martinez-Augustin, Fermin Sanchez de Medina
Dec 3, 2008·Cell Metabolism·Christine LonguetDaniel J Drucker
Aug 27, 2009·American Journal of Physiology. Endocrinology and Metabolism·Jing XuMurielle M Véniant
Dec 29, 2009·The Journal of Biological Chemistry·Hiroaki OkazakiGuosheng Liang
May 11, 2010·Gastroenterology·Jody DushayEleftheria Maratos-Flier
Aug 5, 2010·Diabetes·Ffolliott M FisherEleftheria Maratos-Flier
Jun 7, 2011·The American Journal of Pathology·Mahnoush S ShafieiDon C Rockey
Feb 9, 2012·Proceedings of the National Academy of Sciences of the United States of America·Wei WeiYihong Wan
Nov 9, 2012·Expert Opinion on Drug Safety·Michele BortoliniBogdana Balas
Mar 29, 2013·PloS One·Alexei KharitonenkovDavid E Moller
May 15, 2013·Cell Metabolism·William L HollandPhilipp E Scherer
Sep 4, 2013·Endocrine Connections·Karim GarianiFrançois R Jornayvaz
Sep 10, 2013·Cell Metabolism·Gregory GaichDavid E Moller
Jan 1, 2012·Molecular Metabolism·Andrew C AdamsAlexei Kharitonenkov
Jan 28, 2014·The Journal of Clinical Investigation·Aurora MerovciRalph A DeFronzo
Jun 19, 2014·The New England Journal of Medicine·Jacy CrosbySekar Kathiresan
Feb 17, 2015·Molecular Metabolism·Jody R DushayEleftheria Maratos-Flier
Dec 15, 2015·Annual Review of Physiology·Ffolliott Martin Fisher, Eleftheria Maratos-Flier
Jan 5, 2016·Cell Metabolism·Saswata TalukdarSteven A Kliewer
Mar 5, 2016·Journal of Translational Medicine·Dandan GuanJie Yu
Jun 14, 2016·The New England Journal of Medicine·Steven P MarsoUNKNOWN LEADER Trial Investigators
Aug 10, 2016·Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research·Xiaodong LiJing Xu
Aug 23, 2016·The Journal of Clinical Investigation·Adriano MaidaAdam J Rose
Jun 22, 2017·International Journal of Molecular Sciences·Arunkumar E Achari, Sushil K Jain

❮ Previous
Next ❯

Citations

Jan 1, 2021·Molecular Metabolism·Saswata Talukdar, Alexei Kharitonenkov
Dec 29, 2020·Molecular Metabolism·Brian FinanBin Yang
Mar 25, 2021·Nature Metabolism·Kyle H Flippo, Matthew J Potthoff
Apr 16, 2021·Expert Opinion on Emerging Drugs·Jonathan Andrew FallowfieldAndrew Robertson
Apr 20, 2021·Frontiers in Cardiovascular Medicine·Junbin YanBeihui He
May 28, 2021·Rejuvenation Research·Jasmine W LarrickJames W Larrick
Jul 3, 2021·International Journal of Molecular Sciences·Siarhei A DabravolskiAlexander N Orekhov
Jun 14, 2021·Reviews in Endocrine & Metabolic Disorders·Shuang HuaDewei Ye
Aug 26, 2021·The Journal of Clinical Endocrinology and Metabolism·Daniel J RaderUNKNOWN CLLF580X2102 study team
Oct 7, 2021·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Qiang-Jun WangZhong-Hong Wu
Nov 5, 2021·Laboratory Investigation; a Journal of Technical Methods and Pathology·Kota YanoYoshito Itoh

❮ Previous
Next ❯

Methods Mentioned

BETA
targeted mutations

Clinical Trials Mentioned

NCT01856881
NCT03976401
NCT03967401
NCT01492465

Software Mentioned

lme4
emmeans
GraphPad
R
nlme

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.